Idorsia Company Description

Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland.

The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases.

Its products include PIVLAZ (clazosentan), available in 150 mg, is indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage securing; and QUVIVIQ (daridorexant) for the treatment of adult patients with insomnia.

The company has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and commercialize PIVLAZ.

It also has a collaboration with Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy.

The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.

Idorsia Ltd

Country	Switzerland
Founded	2017
Industry	Biotechnology
Sector	Healthcare
Employees	650
CEO	Jean-Paul Clozel

Contact Details

Address: Hegenheimermattweg 91 Allschwil, 4123 Switzerland
Phone	41 58 844 10 10
Website	idorsia.com

Stock Details

Ticker Symbol	IDIA
Exchange	SIX Swiss Exchange
Reporting Currency	CHF
ISIN Number	CH0363463438
SIC Code	2836